Grail
GenomeWeb Top 40 Falls 6 Percent in March, Tracking Decline in Broader Market
The Dow Jones Industrial Average fell 4 percent while the Nasdaq fell 8 percent and the Nasdaq Biotech Index declined by 6 percent.
Grail Q4 Revenues Jump 26 Percent on Strong Galleri Cancer Detection Test Sales
Galleri revenue grew 39 percent year over year to $31.6 million, and the company said that it sold more than 137,000 Galleri tests in 2024.
Grail Stock Surges on Quest Diagnostics Integration of Galleri MCED Test
Physicians in the US can now order the blood-based multi-cancer early detection assay through Quest.
GenomeWeb Top 40 Rises 10 Percent in January, Outpacing Gains in Broader Market
The Dow Jones Industrial Average rose 5 percent while the Nasdaq rose 2 percent, and the Nasdaq Biotech Index rose 5 percent.
JP Morgan Healthcare Conference, Day 3: Grail, Ultima Genomics, Seer, GeneDx, Quanterix
Highlights from the third day included Quanterix's announcement of a new protein detection platform, to be launched later this year.
Nov 12, 2024
Grail Q3 Revenues Rise 39 Percent
Jun 24, 2024
Illumina Completes Grail Divestment
May 13, 2024